Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis

Phase 4

Recruiting

• Conditions: Takayasu Arteritis
• Interventions: Drug: Tofacitinib; Drug: Methotrexate

• Registration Number: NCT05102448
• Lead Sponsor: Shanghai Zhongshan Hospital

Brief Summary

The aim of this study is to evaluate and compare the efficacy and safety of tofacitinib and methotrexate based on prednisone therapy in patients with Takayasu arteritis

Detailed Description

Takayasu's arteritis (TAK), a chronic large vessel vasculitis, involves the aorta and its main branches. Glucocorticoids and immunosuppressants such as methotrexate, cyclophosphamide are common agents for TAK treatment. However, their effects for remission induction and relapse prevention are not satisfied. More effective agents for TAK treatment remain to be investigated. Tofacitinib (TOF) is a Jak inhibitor, which has been proved to be effective in multiple autoimmune diseases such as rheumatoid arthritis. Our preliminary real-world study also demonstrated a promising treatment effect of TOF in patients with TAK. But its efficacy and safety needs further verification. The present randomized controlled trial aimes to compare efficacy between methotrexate and tofacitinib in TAK treatment.

Study Timeline

• Study First Submitted: 2021-10-19
• Study First Submitted QC: 2021-10-19
• Study Start: 2021-11-01
• Study First Posted: 2021-11-01
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-09
• Last Update Posted: 2024-10-14
• Primary Completion: 2025-12-31
• Study Completion: 2025-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 76

Inclusion Criteria

1. Patients met 1990 American College of Rheumatology (ACR) classification criteria or 2018 ACR classification criteria (draft) of TAK
2. Women or men aged 18-65
3. All patients agreed that there is no fertility plan during clinical trials, and the results of female serum or urinary pregnancy tests must be negative
4. Active TAK patients according to NIH disease activity criteria
5. All patients agreed to sign the informed consent

Exclusion Criteria

1. Patients with organ failure who accord to one or more of the following conditions:

   I.Heart function New York class 4 II.Glomerular filtration rate ≤ 60ml/min III.Liver function Child grade 2 and above IV.High-frequency melanoma (attacks for 3 consecutive days) V.Acute cerebral infarction or cerebral hemorrhage VI.Blood pressure > 160/100mmHg

2. Patients who received revascularization surgery related to the treatment of TAK within 3 months (except balloon dilatation); balloon dilatation or surgery unrelated to TAK within 1 month

3. Patients who have other autoimmune diseases (e.g. ANCA-associated vasculitis, systemic lupus erythematosus, Behcet's disease, etc.)

4. Patients with severe, progressive or uncontrolled comorbidities of kidney, liver, blood system, gastrointestinal, lung, heart, etc or other coexisting medical conditions that may exert unexpected risks

5. Patients with concomitant diseases, such as asthma, that may require additional medium to high doses of glucocorticoids (prednisone ≥ 10mg/ days or equivalent dose) during the study period

6. Patients with active infections with HBV, HCV, tuberculosis or other serious acute or chronic infections

7. Patients with malignancies

8. Patients with one or more of the following abnormal laboratory examinations I.Serum ALT or AST ≥ 1.5 times the normal upper limit; II.White blood cell count ≤ 4 × 109/L III.Platelet count ≤ 100x109/L IV.Hemoglobin < 85g/L V.Other abnormal laboratory tests that may cause unacceptable risks

9. Patients allergic to the experimental drug

10. Patients who have ever failed to tofacitinib or methotrexate after 3 months' treatment in previous medical history

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Tofacitinib	Tofacitinib	Partcipants would be given one tablet of tofacitinib (5mg per tablet), twice per day, the treatment duration will last 12 months during the whole follow-up period.
Methotrexate	Methotrexate	Participates would be given tablets of methotrexate (2.5mg per tablet) 15mg each week, the treatment duration will last 12 months during the whole follow-up period.

Primary Outcome Measures

Name	Time	Method
The effectiveness rate after 6 months' treatment	From the enrollment to the end of 6 months	The effectiveness rate equals to patients who achieved this goal /patients at the end of 6 months. The effectiveness was defined as satisfying three of the following 1)-4) criteria and the 5) criteria: 1) no systemic symptoms such as weakness, weight loss, etc; 2) no new ischemic symptoms or signs; 3) normal erythrocyte sedimentation rate (ESR); 4) no new vascular progression or new lesions upon imaging; 5) GCs is tapered to 10mg qd and this dosage is maintained for 4 weeks.

Secondary Outcome Measures

Name	Time	Method
The remission rate with GCs 7.5mg qd at the end of 12 months	From the enrollment to the the end of 12 months	Ratio of patients who achieved remission with GCs 7.5mg qd at the end of 12 months. The remission is defined as satisfying three of the following 1)-4) criteria: 1) no systemic symptoms such as weakness, weight loss, etc; 2) no new ischemic symptoms or signs; 3) normal erythrocyte sedimentation rate (ESR); 4) no new vascular progression or new lesions upon imaging. It is required that GCs 7.5mg qd should be maintained at least for four weeks.
Relapse free survival rate	From the enrollment to the the end of 12 month	Ratio of patients without relapse after achieving remission during the 12 months follow-up
The cumulative dosage of GCs during the whole period of 12-months follow-up	From the enrollment to the the end of 12 months	The cumulative dosage = Sum of doses of prednisone （or equivalents） each day
Side effects rate	From the enrollment to the the end of 12 months	Ratio of patients with side effects. All the kinds of adverse event related to the treatment and the disease itself will be recorded.

Trial Locations

Locations (1)

Lindi Jiang; 🇨🇳 Shanghai, Shanghai, China